Portal Biotechnologies Secures $9 Million for Cell Engineering Expansion
June 23, 2026, 3:37 pm
Portal Biotechnologies landed $9 million. This funding round, led by NFX, will propel commercial scaling of its cell engineering and drug discovery platform. The company's proprietary mechanoporation technology efficiently delivers complex molecules into hard-to-transfect cells. This innovation addresses a major biological bottleneck. Portal plans expansion into novel drug discovery workflows, cost-effective AI data generation, and advanced cell therapies. Over 100 customers, including Merck, AbbVie, and Microsoft, leverage its platform. Key collaborations involve mapping immune responses with Microsoft/Ragon and developing portable cell therapy devices with DARPA. This capital fuels the next wave of precision medicine and biotechnological advancement.
Portal Biotechnologies announced a major funding round. The company secured $9 million. This oversubscribed financing round positions Portal for significant growth. NFX led the investment. Key existing investors also participated. These included IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures. This capital infusion will fuel the company’s ambitious expansion.
Portal operates at the forefront of cell engineering. It builds crucial infrastructure for drug discovery. Its work also extends to advanced cell therapies. The company’s proprietary platform is its core strength. This platform utilizes mechanoporation. Mechanoporation enables efficient molecule delivery. It handles a wide range of biological cargo. This includes RNA, gene editors, probes, and other complex molecules. Its unique advantage lies in its ability to target hard-to-transfect cells. It works across diverse cell types. It supports various research workflows.
Biology faces a significant hurdle. Delivering complex molecules safely into cells is a challenge. Maintaining cell function is equally vital. Portal’s technology directly addresses this bottleneck. It offers a scalable solution. This allows researchers to manipulate cells effectively. Cell integrity remains uncompromised. This capability is transformative for modern biology. It accelerates discovery. It paves the way for new therapies.
The new funding targets three critical expansion areas. First, it supports novel drug discovery workflows. Second, it drives cost-effective multi-perturbation AI data generation. Third, it enables development of next-generation cell therapies. These efforts involve close collaboration. Portal partners with leading academic institutions. It also works with major biopharma companies. These strategic alliances maximize impact. They accelerate innovation across the life sciences sector.
Portal boasts impressive commercial traction. It has surpassed 100 customers. These clients include top pharma giants. Leading AI companies also utilize its platform. Prominent biology research centers are among its users. Esteemed academic institutions also rely on Portal's technology. Publicly highlighted organizations showcase its reach. These include Microsoft, Merck, AbbVie, Mass General Brigham, the Ragon Institute, and Purdue University.
Researchers from Merck, AbbVie, and Purdue University have presented on Portal’s applications. Their work spans diverse areas. These include screening impermeable degraders. They also leverage the platform for peptide molecule analysis. DNA-encoded library assays benefit from the technology. Target-engagement assays also show strong results. These applications demonstrate the platform’s versatility. They confirm its utility in advanced research. Many pharma customers have upgraded. They now use Portal’s high-throughput Galaxy-i platform. This system launched earlier this year. Its adoption signals strong market demand.
Collaborations extend into cutting-edge research. Portal works with the Ragon Institute. This institute combines expertise from Harvard, MIT, and Mass General Brigham. Microsoft is also a key partner. This two-year project focuses on generating model training data. It aims to map immune responses at scale. This initiative leverages Portal's platform for high-throughput data generation. Such data is critical for AI-driven biological insights. Additional collaborations in multi-perturbation screens are also underway. These projects push the boundaries of biological understanding.
Cell therapy represents another major focus. DARPA recognized Portal’s innovative potential. It expanded an initial $8 million contract. This contract supports a specific goal. Portal will develop a portable, field-deployable device. This device will enable rapid point-of-care cell therapy production. DARPA now supports commercialization of this technology. This occurs through its Embedded Entrepreneur Initiative program. This program helps transition promising technologies from research to practical application. It underscores the national security implications of accessible cell therapies.
Mass General Brigham also highlighted Portal's platform. They presented findings at ASGCT. Their work focused on same-day CAR-T production. This involved circRNA-based multifunctional CAR-T cells. This application promises to revolutionize cell therapy manufacturing. It reduces complexity and turnaround time. This makes advanced therapies more accessible. It could improve patient outcomes.
Portal’s platform integrates seamlessly. It works with high-throughput robotics. It also connects with GMP manufacturing systems. This integration supports next-generation discovery. It lays groundwork for future point-of-care cell therapy manufacturing. This holistic approach ensures scalability. It also guarantees regulatory compliance. It bridges the gap between research and clinical application.
The company's vision is clear. It aims to provide universal infrastructure for cell engineering. This vision underpins future drug discovery. It supports the evolving TechBio landscape. It empowers advanced cell therapy ecosystems. This recent funding solidifies its position. It enables further innovation. It accelerates its impact on global health challenges. Portal is driving the next wave of biotechnological advancement. Its technology promises to unlock new biological possibilities. It enhances human health through precision engineering.
Portal Biotechnologies announced a major funding round. The company secured $9 million. This oversubscribed financing round positions Portal for significant growth. NFX led the investment. Key existing investors also participated. These included IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures. This capital infusion will fuel the company’s ambitious expansion.
Portal operates at the forefront of cell engineering. It builds crucial infrastructure for drug discovery. Its work also extends to advanced cell therapies. The company’s proprietary platform is its core strength. This platform utilizes mechanoporation. Mechanoporation enables efficient molecule delivery. It handles a wide range of biological cargo. This includes RNA, gene editors, probes, and other complex molecules. Its unique advantage lies in its ability to target hard-to-transfect cells. It works across diverse cell types. It supports various research workflows.
Biology faces a significant hurdle. Delivering complex molecules safely into cells is a challenge. Maintaining cell function is equally vital. Portal’s technology directly addresses this bottleneck. It offers a scalable solution. This allows researchers to manipulate cells effectively. Cell integrity remains uncompromised. This capability is transformative for modern biology. It accelerates discovery. It paves the way for new therapies.
The new funding targets three critical expansion areas. First, it supports novel drug discovery workflows. Second, it drives cost-effective multi-perturbation AI data generation. Third, it enables development of next-generation cell therapies. These efforts involve close collaboration. Portal partners with leading academic institutions. It also works with major biopharma companies. These strategic alliances maximize impact. They accelerate innovation across the life sciences sector.
Portal boasts impressive commercial traction. It has surpassed 100 customers. These clients include top pharma giants. Leading AI companies also utilize its platform. Prominent biology research centers are among its users. Esteemed academic institutions also rely on Portal's technology. Publicly highlighted organizations showcase its reach. These include Microsoft, Merck, AbbVie, Mass General Brigham, the Ragon Institute, and Purdue University.
Researchers from Merck, AbbVie, and Purdue University have presented on Portal’s applications. Their work spans diverse areas. These include screening impermeable degraders. They also leverage the platform for peptide molecule analysis. DNA-encoded library assays benefit from the technology. Target-engagement assays also show strong results. These applications demonstrate the platform’s versatility. They confirm its utility in advanced research. Many pharma customers have upgraded. They now use Portal’s high-throughput Galaxy-i platform. This system launched earlier this year. Its adoption signals strong market demand.
Collaborations extend into cutting-edge research. Portal works with the Ragon Institute. This institute combines expertise from Harvard, MIT, and Mass General Brigham. Microsoft is also a key partner. This two-year project focuses on generating model training data. It aims to map immune responses at scale. This initiative leverages Portal's platform for high-throughput data generation. Such data is critical for AI-driven biological insights. Additional collaborations in multi-perturbation screens are also underway. These projects push the boundaries of biological understanding.
Cell therapy represents another major focus. DARPA recognized Portal’s innovative potential. It expanded an initial $8 million contract. This contract supports a specific goal. Portal will develop a portable, field-deployable device. This device will enable rapid point-of-care cell therapy production. DARPA now supports commercialization of this technology. This occurs through its Embedded Entrepreneur Initiative program. This program helps transition promising technologies from research to practical application. It underscores the national security implications of accessible cell therapies.
Mass General Brigham also highlighted Portal's platform. They presented findings at ASGCT. Their work focused on same-day CAR-T production. This involved circRNA-based multifunctional CAR-T cells. This application promises to revolutionize cell therapy manufacturing. It reduces complexity and turnaround time. This makes advanced therapies more accessible. It could improve patient outcomes.
Portal’s platform integrates seamlessly. It works with high-throughput robotics. It also connects with GMP manufacturing systems. This integration supports next-generation discovery. It lays groundwork for future point-of-care cell therapy manufacturing. This holistic approach ensures scalability. It also guarantees regulatory compliance. It bridges the gap between research and clinical application.
The company's vision is clear. It aims to provide universal infrastructure for cell engineering. This vision underpins future drug discovery. It supports the evolving TechBio landscape. It empowers advanced cell therapy ecosystems. This recent funding solidifies its position. It enables further innovation. It accelerates its impact on global health challenges. Portal is driving the next wave of biotechnological advancement. Its technology promises to unlock new biological possibilities. It enhances human health through precision engineering.